JAMA Cardiol
Published Online: November 8, 2025
Today at the AHA congress in New Orleans, BridgeBio presented data showing that acoramidis significantly reduces all-cause mortality (through month 42) in people living with hereditary ATTR-CM population, with specific benefit noted in those living with the V122i variant. These data have also been published today in JAMA Cardiology.
You can read more information about this in our press release: https://bit.ly/4nKaCRz
